Glimestar-M3 Forte Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 3 mg and Metformin 1000 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to better glucose uptake and utilization. The prolonged-release formulation of Glimestar-M3 Forte ensures a sustained therapeutic effect, promoting stable blood glucose levels throughout the day and minimizing peak-related side effects. This combination is particularly beneficial for patients inadequately controlled on monotherapy with either agent alone or those requiring dual therapy to achieve optimal glycemic targets. It should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular monitoring of blood glucose levels. Caution is advised in patients with renal or hepatic impairment, and it is contraindicated in conditions such as diabetic ketoacidosis or severe renal dysfunction. Common adverse effects may include gastrointestinal disturbances and hypoglycemia. Regular follow-up and dose adjustments based on glycemic response and tolerability are recommended to ensure safe and effective use of Glimestar-M3 Forte Tablet PR.